Critical Aspects to be Considered Prior to Large-Scale Production of Peptides

Title:Critical Aspects to be Considered Prior to Large-Scale Production of Peptides

Volume: 14 Issue: 7

Author(s): Kelly Cristina Leite Mulder, Antônio Américo Barbosa Viana, Mauro Xavier and Nádia Skorupa Parachin

Affiliation:

Keywords: Calcitonin, chemical synthesis, Fuzeon, Glucagon, heterologous expression, Pexiganan, Sandostatin, scale-up.

Abstract: Numerous peptides are available on the market as therapeutic drugs for regulating tumor growth, microorganism proliferation, immune response and/or metabolic disorders. Peptides are produced either by chemical synthesis or heterologous expression. Independent of the method chosen, there are challenges to transferring its production from the bench (~mg/L) to the industrial (~g/L) scale. Thus, the main scale-up pitfalls for the two methods of peptide production are reviewed here, including the advantages of each. Moreover, there will be a special focus on the main challenges for large-scale, heterologous production systems. Peptides that are currently available on the market are also described with an emphasis on how their process optimization has been designed in order to develop a cost-effective product.

Cite this article as:

Mulder Cristina Leite Kelly, Viana Américo Barbosa Antônio, Xavier Mauro and Parachin Skorupa Nádia, Critical Aspects to be Considered Prior to Large-Scale Production of Peptides, Current Protein & Peptide Science 2013; 14(7) . https://dx.doi.org/10.2174/13892037113149990071